A groundbreaking study has unveiled the potential of lab-made proteins in combating neurodegenerative diseases like Alzheimer's. These synthetic protein polymers show promise in mitigating conditions such as Alzheimer's, Parkinson's and ALS. By targeting the interaction between proteins Keap1/Nrf2, scientists have developed a potent therapeutic strategy. This therapeutic strategy can alleviate damage caused by oxidative stress. The study marks a notable breakthrough, as the proteins show stability, cellular penetration and resistance to degradation. This innovative approach opens new possibilities for treating Alzheimer's and Parkinson's, where traditional methods have faced challenges. "We established Nrf2 as a principal target for the treatment of neurodegenerative diseases over the past two decades, but this novel approach for activating the pathway holds great promise to develop disease-modifying therapies," says Jeffrey Johnson, co-author, The University of Wisconsin-Madison.
Healthtech Startup Avey Is On A Mission To Empower Individuals Worldwide With A Free, Anytime-Anywhere Self-Diagnosis Tool
Avey's AI medical diagnostic algorithm replaces the need for self-diagnosis via search engines by offering a reliable, accurate alternative. Digital health technologies are designed to empower patients with data-driven insights into their health. The influx of everyday medical monitoring devices and …